CEACAM5 and neoplasm: Flow cytometry analysis of treated tumors, harvested 24 h after third infusion of the molecules, revealed that, similar to studies in humanized mice, CEA-TCB monotherapy increased the frequency of intra-tumor T-cells with preferential increase of CD8 T-cells over CD4 T-cells, leading to an increased ratio of intra-tumor CD8/CD4 and CD8/Tregs (Figure 5B).